Literature DB >> 29239400

Post-operative antibiotics following placement of a penile prosthesis.

Alex Tatem1, Jason R Kovac2.   

Abstract

Entities:  

Year:  2017        PMID: 29239400      PMCID: PMC5715177          DOI: 10.21037/tau.2017.11.14

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


× No keyword cloud information.
One of the most devastating complications that can occur following a penile prosthesis is infectious in nature (1,2). Consequently, both proper patient selection and risk management are essential for prosthetic surgeons. In a recent paper by Palma-Zamora et al. (1) published in the current issue of Translational Andrology and Urology, the authors present data discussing the short-term (30-day) adverse outcomes that can occur post placement of a penile prosthesis. The authors identified an overall 30-day complication rate of 11%; of which 45% were infectious in etiology (1). Diabetes was present in 29% of patients (1) and although there is some debate regarding the importance of hemoglobin A1c in diabetic patients undergoing prosthesis placement, optimizing peri-operative glucose control for all diabetic patients is essential in reducing the risk of infectious complications (3,4). Given the significant consequences of infection, a brief discussion regarding post-operative antibiotic usage is warranted. In a 2013 consensus statement of 16 top prosthetic surgeons, anywhere from 5–14 days of post-operative oral antibiotics was preferred (5). A multitude of different oral antibiotics were used including quinolones, cephalosporins, penicillins and sulfa drugs (5). In geographic regions where methicillin-resistant Staphylococcus aureus (MRSA) was prevalent, the consensus was to use trimethoprim-sulfamethoxazole (Bactrim) or, in cases of sulfa drug allergy, doxycycline (5). Unfortunately, given the current state of research and methodological challenges, expert opinion is the best level of evidence available. While no randomized controlled trials to support this practice, recent case reports and small retrospective studies have found success in managing even local infections with conservative measures that include oral antibiotics (6,7). At the present time, although further study is required, the use of post-operative prophylactic antibiotic usage is justified.
  6 in total

1.  Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin.

Authors:  S K Wilson; C C Carson; M A Cleves; J R Delk
Journal:  J Urol       Date:  1998-05       Impact factor: 7.450

Review 2.  Penile Prosthesis Infections-A Review of Risk Factors, Prevention, and Treatment.

Authors:  Miguel Pineda; Arthur L Burnett
Journal:  Sex Med Rev       Date:  2016-05-13

3.  Conservative Therapy is an Effective Option in Patients With Localized Infection After Penile Implant Surgery.

Authors:  Mohamad Habous; Mohammed Farag; Ben Williamson; Osama Laban; Saad Mahmoud; Osama Abdelwahab; Mohamed Elkhouly; Usama Kamil; Saleh Binsaleh; Raanan Tal; David Ralph; John P Mulhall
Journal:  J Sex Med       Date:  2016-05-06       Impact factor: 3.802

4.  North American consensus document on infection of penile prostheses.

Authors:  Rabih O Darouiche; Anthony J Bella; Timothy B Boone; Gerry Brock; Gregory A Broderick; Arthur L Burnett; Raphael Carrion; Culley Carson; Brian Christine; Chipriya B Dhabuwala; Lawrence S Hakim; Gerard Henry; LeRoy A Jones; Mohit Khera; Drogo K Montague; Ajay Nehra
Journal:  Urology       Date:  2013-08-16       Impact factor: 2.649

Review 5.  Diabetes and Risk of Surgical Site Infection: A Systematic Review and Meta-analysis.

Authors:  Emily T Martin; Keith S Kaye; Caitlin Knott; Huong Nguyen; Maressa Santarossa; Richard Evans; Elizabeth Bertran; Linda Jaber
Journal:  Infect Control Hosp Epidemiol       Date:  2015-10-27       Impact factor: 3.254

6.  Local Treatment of Penile Prosthesis Infection as Alternative to Immediate Salvage Surgery.

Authors:  Saturnino Luján; Ramón Rogel; Enrique Broseta; Francisco Boronat
Journal:  Sex Med       Date:  2016-07-30       Impact factor: 2.491

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.